How Can Biopharma Take on Scope 3 Carbon Emissions?

September 5, 2024 EcoVadis EN


When Cytiva recently surveyed the biopharma industry to gain insights into sustainability progress, there was good news and bad news. Companies are succeeding in managing Scope 1 and 2 carbon emissions (Scope 1 covers direct emissions from owned or controlled sources, while Scope 2 covers indirect emissions resulting from the purchase of electricity, steam, heat or cooling)—but when it comes to Scope 3, struggles persist.



Read the full article at: www.genengnews.com

Read more...

About the Author

EcoVadis EN

EcoVadis is a purpose-driven company dedicated to embedding sustainability intelligence into every business decision worldwide. We offer a full range of solutions including IQ-Plus Risk & Compliance Management, EcoVadis Ratings, and Carbon Action Module for Scope 3 Decarbonization. Key features like 360/Live News Monitoring, Academy E-learning and Corrective action plans help companies comply with ESG regulations, reduce GHG emissions, and improve the sustainability performance of their business and value chain across 250 industries in 185 countries.

Follow on Twitter Follow on Linkedin Visit Website More Content by EcoVadis EN
Previous Article
Packaging designs go all-in on recyclability
Packaging designs go all-in on recyclability

Packaging designs are increasingly prioritising recyclability, from the selection of sustainable materials ...

Next Article
McBride's Surcare cuts plastic with Elopak carton switch
McBride's Surcare cuts plastic with Elopak carton switch

European manufacturer of cleaning and hygiene products McBride has announced a significant step towards sus...